Literature DB >> 24630631

[The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists].

Laurent Villeneuve1, Sylvie Isaac2, Olivier Glehen3, Mathieu Capovilla4, Anne Chevallier5, Sabrina Croce6, Peggy Dartigues7, Juliette Fontaine8, Rachid Kaci9, Gerlinde Lang-Averous10, Marie-Hélène Laverriere11, Agnès Leroux-Broussier12, Eliane Mery13, Flora Poizat14, Séverine Valmary-Degano15, Véronique Verriele-Beurrier16, François-Noël Gilly3, Frédéric Bibeau17.   

Abstract

As part of the national 2009-2013 Cancer Plan, and with the support of the National cancer Institute and the French ministry of health, the National network for the treatment of rare peritoneal malignancies (RENAPE) has been organized. Its main objective is to optimize the framework for the healthcare management and treatment of rare peritoneal malignancies. This specific organization covers the whole national territory including clinical expert and specialized structures and should lead to an appropriate treatment based on expertise and proximity. Within the RENAPE network, the RENA-PATH group gathers the pathologists actively involved in the management of rare peritoneal malignancies. The actions of RENA-PATH are focused primarily on the harmonization of pathological diagnostic criteria, reporting of new cases in the RENAPE registry and histology reviewing.
Copyright © 2014. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cancer; Mesothelioma; Mésothéliome; Network; Peritoneum; Pseudomyxoma; Pseudomyxome; Péritoine; Rare; Réseau

Mesh:

Year:  2014        PMID: 24630631     DOI: 10.1016/j.annpat.2014.01.008

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  4 in total

1.  Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.

Authors:  Nazim Benzerdjeb; Peggy Dartigues; Vahan Kepenekian; Séverine Valmary-Degano; Eliane Mery; Gerlinde Avérous; Anne Chevallier; Marie-Hélène Laverriere; Irène Villa; Olivier Harou; Françoise Galateau Sallé; Laurent Villeneuve; Olivier Glehen; Sylvie Isaac; Juliette Hommell-Fontaine; Frédéric Bibeau
Journal:  Virchows Arch       Date:  2021-04-14       Impact factor: 4.064

2.  FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.

Authors:  Julien Dubreuil; Francesco Giammarile; Pascal Rousset; Naoual Bakrin; Guillaume Passot; Sylvie Isaac; Olivier Glehen; Andrea Skanjeti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-24       Impact factor: 9.236

3.  Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.

Authors:  Nazim Benzerdjeb; Peggy Dartigues; Vahan Kepenekian; Séverine Valmary-Degano; Eliane Mery; Gerlinde Averous; Anne Chevallier; Marie-Hélène Laverriere; Irène Villa; Françoise Galateau Sallé; Laurent Villeneuve; Olivier Glehen; Sylvie Isaac; Juliette Hommell-Fontaine
Journal:  Virchows Arch       Date:  2021-06-24       Impact factor: 4.064

4.  The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Authors:  L Villeneuve; G Passot; O Glehen; S Isaac; F Bibeau; P Rousset; F N Gilly
Journal:  Orphanet J Rare Dis       Date:  2017-02-17       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.